MedElevator
Войти в исследования Current opinion in nephrology and hypertension · 2026
Diagnosis and treatment of immune checkpoint inhibitor induced kidney disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mistry Kavita, Best Roya, Stueber Christopher T, Sise Meghan E
Аннотация
PURPOSE OF REVIEW: The use of immune checkpoint inhibitors (ICIs) is expanding in the treatment of a variety of cancer types; however, treatment with ICIs may result in off-target kidney inflammation in 3-5% of patients, most commonly acute interstitial nephritis (AIN). There is a significant unmet need for noninvasive diagnostic tools to facilitate accurate and timely diagnosis, and for targeted therapeutic strategies to more specifically block inflammation in ICI-AIN.
RECENT FINDINGS: The most promising emerging noninvasive diagnostic strategies include novel urinary biomarkers such as C-X-C motif ligand 9 (CXCL9), tumor necrosis factor alpha (TNF-α), interleukin 5 (IL-5), and Fas. There are increasing data to support treatment strategies that may better preserve the antitumor effect of ICIs, including the use of infliximab, as well as shorter corticosteroid courses.
SUMMARY: Novel biomarkers have shown great potential, although further studies will be required for validation. Improving scientific understanding of the underlying immunobiology in ICI-AIN and other ICI toxicities may uncover new pathways amenable to more specific therapeutic targeting, such as TNF-α. General nephrologists should be aware of recent advances in biomarker discovery and second-line immunosuppressives, given the increasingly widespread use of ICIs.
RECENT FINDINGS: The most promising emerging noninvasive diagnostic strategies include novel urinary biomarkers such as C-X-C motif ligand 9 (CXCL9), tumor necrosis factor alpha (TNF-α), interleukin 5 (IL-5), and Fas. There are increasing data to support treatment strategies that may better preserve the antitumor effect of ICIs, including the use of infliximab, as well as shorter corticosteroid courses.
SUMMARY: Novel biomarkers have shown great potential, although further studies will be required for validation. Improving scientific understanding of the underlying immunobiology in ICI-AIN and other ICI toxicities may uncover new pathways amenable to more specific therapeutic targeting, such as TNF-α. General nephrologists should be aware of recent advances in biomarker discovery and second-line immunosuppressives, given the increasingly widespread use of ICIs.